Cargando…

Safety assessment of gadolinium-based contrast agents (GBCAs) requires consideration of long-term adverse effects in all human tissues

Detalles Bibliográficos
Autor principal:	Goischke, Hans-Klaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408503/ https://www.ncbi.nlm.nih.gov/pubmed/28607758 http://dx.doi.org/10.1177/2055217317704450

Ejemplares similares

Gadolinium retention in a rat model of subtotal renal failure: are there differences among macrocyclic GBCAs?
por: Bonafè, Roberta, et al.
Publicado: (2023)

How the Chemical Properties of GBCAs Influence Their Safety Profiles In Vivo
por: Do, Quyen N., et al.
Publicado: (2021)

An NMR relaxometry approach for quantitative investigation of the transchelation of gadolinium ions from GBCAs to a competing macromolecular chelator
por: Werner, Patrick, et al.
Publicado: (2021)

Impact of Treatment With Chelating Agents Depends on the Stability of Administered GBCAs: A Comparative Study in Rats
por: Boyken, Janina, et al.
Publicado: (2019)

Gadolinium contrast agents: Over exposure?
por: Biederman, Robert W, et al.
Publicado: (2016)

Subsequent MRI of pediatric patients after an adverse reaction to Gadolinium-based contrast agents
por: Hojreh, Azadeh, et al.
Publicado: (2020)

Gadolinium-DTPA: A New Contrast Agent
por: Niendorf, H. P.
Publicado: (1988)

Linear Gadolinium-Based Contrast Agents Are Associated With Brain Gadolinium Retention in Healthy Rats
por: Robert, Philippe, et al.
Publicado: (2016)

Gadolinium-Based Contrast Agents in Pregnant Women: A Literature Review of MRI Safety
por: Alghamdi, Sami A
Publicado: (2023)

Review of the Efficacy and Safety of Gadopiclenol: A Newly Emerging Gadolinium-Based Contrast Agent
por: Alsogati, Emad, et al.
Publicado: (2023)

Gadolinium Complexes as Contrast Agent for Cellular NMR Spectroscopy
por: Sakol, Nat, et al.
Publicado: (2020)

Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents
por: Thomsen, Henrik S., et al.
Publicado: (2007)

Biocompatible Polyhydroxyethylaspartamide-based Micelles with Gadolinium for MRI Contrast Agents
por: Jeong, Sang Young, et al.
Publicado: (2010)

Immediate reaction to gadolinium based contrast agent with fatal outcome()()()
por: Behzadi, Ashkan Heshmatzadeh, et al.
Publicado: (2018)

Gadolinium-Based Contrast Agents Hypersensitivity: A Case Series
por: Nucera, Eleonora, et al.
Publicado: (2021)

Gadolinium-based contrast agents in neurofibromatosis type 1 (Review)
por: Năstase, Florentina, et al.
Publicado: (2021)

Recent Advances in Gadolinium Based Contrast Agents for Bioimaging Applications
por: Fatima, Atiya, et al.
Publicado: (2021)

The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity - A systematic review
por: Olchowy, Cyprian, et al.
Publicado: (2017)

Gadolinium deposition in the brain of dogs after multiple intravenous administrations of linear gadolinium based contrast agents
por: Richter, Henning, et al.
Publicado: (2020)

Long-Term Evaluation of Gadolinium Retention in Rat Brain After Single Injection of a Clinically Relevant Dose of Gadolinium-Based Contrast Agents
por: Strzeminska, Izabela, et al.
Publicado: (2020)

Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T(1) contrast
por: Ananta, Jeyarama S., et al.
Publicado: (2010)

Gadolinium retention within multiple rat organs after intra-articular administration of gadolinium-based contrast agents
por: Ringler, Michael D., et al.
Publicado: (2021)

Gadolinium Retention in the Brain of Mother and Pup Mouse: Effect of Pregnancy and Repeated Administration of Gadolinium‐Based Contrast Agents
por: Yao, Xiang, et al.
Publicado: (2022)

Measurements of signal intensity of globus pallidus and dentate nucleus suggest different deposition characteristics of macrocyclic GBCAs in children
por: Olchowy, Cyprian, et al.
Publicado: (2018)

Thermal Excitation of Gadolinium-Based Contrast Agents Using Spin Resonance
por: Dinger, Steven C., et al.
Publicado: (2016)

Acute respiratory distress syndrome after the use of gadolinium contrast agent
por: Kerget, Bugra, et al.
Publicado: (2018)

The New Restrictions on the Use of Linear Gadolinium-based Contrast Agents in Japan
por: Kanda, Tomonori
Publicado: (2018)

Effect of different doses of gadolinium contrast agent on clinical outcomes in MS
por: Ackermans, Nathalie, et al.
Publicado: (2019)

Investigating the Impact of Gadolinium-Based Contrast Agents on the Corrected QT Interval
por: Gress, Kyle L, et al.
Publicado: (2020)

PEG-modified gadolinium nanoparticles as contrast agents for in vivo micro-CT
por: Cruje, Charmainne, et al.
Publicado: (2021)

Formation of gadolinium–ferritin from clinical magnetic resonance contrast agents
por: Neburkova, Jitka, et al.
Publicado: (2020)

Gadolinium as a contrast agent for infusion sialograms in patients with iodine allergy
por: Sabotin, Ryan P., et al.
Publicado: (2023)

A risk prediction model for contrast-induced nephropathy associated with gadolinium-based contrast agents
por: Zheng, Huanhuan, et al.
Publicado: (2022)

Analytical Interference in Serum Iron Determination Reveals Iron Versus Gadolinium Transmetallation With Linear Gadolinium-Based Contrast Agents
por: Fretellier, Nathalie, et al.
Publicado: (2014)

The interaction between iodinated X‐ray contrast agents and macrocyclic GBCAs provides a signal enhancement in T(1)‐weighted MR images: Insights into the renal excretion pathways of Gd‐HPDO3A and iodixanol in healthy mice
por: Di Gregorio, Enza, et al.
Publicado: (2022)

Vitamin D supplementation for the prevention or depletion of side effects of therapy with alemtuzumab in multiple sclerosis
por: Goischke, Hans-Klaus
Publicado: (2019)

Comorbidities in multiple sclerosis—a plea for interdisciplinary collaboration to improve the quality of life of MS patients
por: Goischke, Hans-Klaus
Publicado: (2019)

Vitamin D Supplementation as Add-on Therapy in Multiple Sclerosis—Balance between Benefit and Risk?: A Commentary on Vitamin D Supplementation in Central Nervous System Demyelinating Disease—Enough Is Enough
por: Goischke, Hans-Klaus
Publicado: (2019)

New Dual Mode Gadolinium Nanoparticle Contrast Agent for Magnetic Resonance Imaging
por: Ghaghada, Ketan B., et al.
Publicado: (2009)

Revisiting the risks of MRI with Gadolinium based contrast agents—review of literature and guidelines
por: Khawaja, Aurang Z., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rkj3t46otf25iff95mu10odjp3